Skip to main content

FY2025 3Q Consolidated Financial Overview

[Based on Japanese GAAP]

Operating Results

Overview of Operating Results

  • Net sales

    54,486 million yen

    YOY 9.1%

  • Operating profit

    4,911 million yen

    YOY (10.6)%

  • Ordinary profit

    4,854 million yen

    YOY (10.9)%

  • Profit attributable to owners of parent

    3,904 million yen

    YOY (4.7)%

  • Earnings per share

    137.59 yen

    YOY (4.8)%

During the nine months ended December 31, 2025, the Japanese economy maintained a moderate recovery trend, supported by improvements in the employment and income conditions as well as the effects of various government policies. However, the outlook remains uncertain due to factors such as the U.S. trade policies, rising raw material costs, and continued domestic inflation.The Group's core ethical pharmaceutical business continued to face challenges, primarily due to the impact of the annual drug price revisions. Despite these circumstances, the Group’s businesses performed steadily, driven by the ethical pharmaceutical and animal health businesses, as well as sales from overseas operations. As a result, net sales increased by 4,560 million yen year on year, reaching 54,486 million yen, up 9.1%. On the profit side, operating profit decreased to 4,911 million yen, down 10.6% year on year, ordinary profit decreased to 4,854 million yen, down 10.9% year on year, and profit attributable to owners of parent decreased to 3,904 million yen, down 4.7% year on year, mainly due to an increase in selling, general and administrative expenses, including research and development expenses.

Segment

Net sales

(Millions of yen)

Segment name 1Q 2Q 3Q Full year
Pharmaceutical business 14,515 29,255 45,332
Animal health business 1,841 3,765 5,759
Overseas businesses 1,226 2,133 3,240
Other businesses 58 99 153

(i) Pharmaceutical business

The pharmaceutical business, which focuses on three therapeutic areas of internal medicine, obstetrics and gynecology, and urology, performed steadily despite the impact of drug price revisions. By product, in the obstetrics and gynecology area, sales of RELUMINA for the treatment of uterine fibroids and endometriosis grew steadily to 8,819 million yen, up 5.9% year on year. In addition, sales of DroEthi for the treatment of dysmenorrhea also increased to 6,353 million yen, up 12.0% year on year, maintaining growth from the previous year. In the internal medicine area, sales of flagship THYRADIN thyroid hormone preparation, increased 8.0% year on year to 6,701 million yen. Sales of poorly absorbable rifamycin antibiotic RIFXIMA also grew significantly, rising 21.5% year on year to 5,978 million yen, partly reflecting the impact of upward drug price revisions. In the urology area, sales of LEUPRORELIN, an LH-RH derivative microcapsule-type sustained-release agent, amounted to 2,963 million yen, down 4.6% year on year.

As a result, segment net sales totaled 45,332 million yen, up 2.9% year on year, while segment profit amounted to 5,822 million yen, down 6.1% year on year.

(ii) Animal health business

Net sales from the animal health business, covering veterinary pharmaceuticals, feed additives, and related products, increased to 5,759 million yen, up 1.0% year on year. Segment profit rose to 368 million yen, up 22.6% year on year.

(iii) Overseas businesses

In the previous fiscal year, the Group added “Overseas Business” to its reportable segments, following the consolidation of Ha Tay Pharmaceutical Joint Stock Company, a pharmaceutical company based in Vietnam. In the overseas business, net sales amounted to 3,240 million yen, and segment profit was 70 million yen.

(iv) Other businesses

In the Other Businesses segment, which includes clinical testing services and medical devices, net sales decreased to 153 million yen, down 7.7% year on year, and the segment loss amounted to 28 million yen, compared with a loss of 25 million yen in the same period of the previous year.

Financial Position

Overview of Financial Position Summary

  • Total assets

    112,699 million yen

    Change from end of previous fiscal year 8.1%

  • Net assets

    74,743 million yen

    Change from end of previous fiscal year 4.1%

  • Equity ratio

    61.0 %

    Change from end of previous fiscal year (1.6)point

Overview of Financial Position

(Assets)

Total assets at the end of the third quarter of the current fiscal year increased by 8,404 million yen from the end of the previous fiscal year, reaching 112,699 million yen. This was mainly attributable to increases in investment securities, accounts receivable, and raw materials and supplies, despite a decrease in cash and deposits.

(Liabilities)

Total liabilities at the end of the third quarter of the current fiscal year increased by 5,475 million yen from the end of the previous fiscal year, to 37,956 million yen. This was mainly due to an increase in long-term borrowings.

(Net assets)

Total net assets at the end of the third quarter of the current fiscal year increased by 2,928 million yen from the end of the previous fiscal year, to 74,743 million yen. This was due to an increase in retained earnings resulting from the recognition of profit attributable to owners of parent as well as an increase in unrealized gains on securities.

As a result, the equity ratio decreased by 1.6 percentage points from the end of the previous fiscal year to 61.0%.